At this year’s China International Import Expo (CIIE), Bayer (OTC: BAYRY) showcased a new stroke drug on its CIIE stand just 10 days after its Chinese approval. The move is emblematic of a broader shift: multinational drugmakers are no longer just bringing new drugs to China; they are putting Chinese-developed drugs on their own global stages. Shanghai Hotline reported that 16 of the world’s top 20 pharmaceutical firms were present, showcasing a strategy where China is both a market and a partner in innovation.
But the balance sheet tells a different story. For years, multinationals dominated by introducing their own global innovations. Now, they are accelerating the entry of their own drugs into China and integrating Chinese R&D into their core pipelines. This shift is reshaping how global pharma operates and how China engages with the global industry. The question for investors is: what does this repositioning mean for valuations, competition, and the future of drug development?
Cutting Development-To-Launch Time
- Accelerated Timelines: Multinational drugs are now receiving “first-in-the-world” approvals in China, cutting development-to-launch time significantly for some products.
- Strategic Integration: Chinese-developed assets, like those from Sino Biopharmaceutical (HK: 1177) and Xianweida Biologics, are being licensed to global majors in multi-billion dollar deals, moving from commercial collaboration to early-stage research.
- Supply Chain Reconfiguration: Multinationals are investing heavily in local Chinese manufacturing to secure supply chains, aiming to reduce dependency on legacy production hubs.
Global Drugs Arrive in China at Unprecedented Speed
The data confirms a dramatic acceleration. On November 5, Asundexian was showcased at Bayer’s CIIE stand just 10 days after its Chinese approval. The drug, the world’s first activated factor XI (FXIa) inhibitor, is for reducing stroke risk in adults with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. According to Bayer, the drug received priority review and was approved in about six months from filing to approval.
This is not an isolated case. Takeda’s new narcolepsy drug was approved in China first, in July, for patients aged 16 and over with type 1 narcolepsy, with commercial supply starting October 15. Novo Nordisk’s once-weekly icodec insulin/semaglutide injection also launched commercially in China first, in July — China was the first country in the world to launch the drug. These cases represent a tangible shift in regulatory strategy. “Our most direct impression is that innovative drugs are entering China faster and faster,” said Zhou Xiaolan, global executive vice president of Bayer’s Pharmaceuticals Division and president of Bayer China, as reported by Shanghai Hotline. “More and more innovative drugs can achieve synchronous development, synchronous registration and even synchronous launch with the world, and the time for Chinese patients to access innovative therapies has clearly shortened.”
But the pipeline is diversifying. Oral GLP-1 agonists, the next frontier in diabetes and obesity, are a key focus. Eli Lilly’s oral orforglipron and Novo Nordisk’s oral semaglutide have both submitted for approval in China. The competition here will be fierce, driven by clinical data, patient suitability, and long-term management needs. The strategy now is not just faster drugs, but a broader range of them.
From Market to Partner: China’s Rise in Global R&D
The most significant story is not just faster approvals. It is the ascent of China’s own R&D into multinational pipelines. At CIIE, Pfizer highlighted its metabolic health product, Enoglutide, a drug independently developed by Hangzhou-based Chinese biotech Xianweida Biologics. In February, Pfizer secured exclusive commercialization rights for Enoglutide in mainland China, while Xianweida remains the marketing authorization holder, responsible for R&D, registration, production and supply — a move that underscores the strategic value of Chinese innovation.
The scale of these deals is staggering. In March, Sanofi licensed a myelofibrosis drug developed by CPTC, a subsidiary of Sino Biopharmaceutical, in a global exclusive licensing deal that included a $135 million upfront payment plus up to $1.395 billion in potential milestone payments and sales royalties. Then, on November 4, Boehringer Ingelheim and Sino Biopharmaceutical announced a deal for six preclinical biotherapeutic projects, involving antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies. The agreement includes $358 million in upfront and near-term payments plus up to $7 billion in potential milestone payments tied to option exercise, development, registration and commercialization.
These agreements represent a clear evolution in the partnership model. The deals have progressed from simple commercialization in China to full global licensing and now to early-stage co-development. Chinese biotechs are no longer just suppliers; they are becoming integral partners in the global innovation process.
Supply Chains and Local Manufacturing: The Next Frontier
Bringing drugs to China is one thing; building a resilient supply chain to support them is another. Multinationals are making substantial capital expenditures to localize production. AstraZeneca has established its cell therapy company in Shanghai’s Lingang area, completing its R&D-to-commercialization footprint in cell therapy, and has begun construction on an upgrade project at its Wuxi production and supply base involving an investment of nearly RMB 200 million. Novartis is investing about RMB 1.5 billion in a new factory campus in Changping, launched in November this year, and is building a radioligand therapy production base in Haiyan, Zhejiang, with an investment of about RMB 600 million, set to be operational in 2027.
Roche is investing RMB 2.04 billion in a Shanghai biologics facility for the localized production of Faricimab, with the company expecting a milestone by the end of this year. These investments are critical.
To ensure new drugs reach patients, companies are building out distribution networks. On November 6, Meituan Medicine & Health launched a “New Specialty Drug Launch Alliance” together with AstraZeneca, Pfizer, Novo Nordisk and other drugmakers and pharmacy chains. The alliance covers more than 100 chain brands and over 50,000 stores, with 85 chains set to open green channels for innovative drugs, aiming to compress the time for a new drug to go from pharmacy shelf to online instant retail to under 30 days. This is a direct response to the challenge of getting complex, new therapies to patients quickly.
What It Means for the Global Industry
This strategic repositioning by multinationals is a direct response to China’s maturing innovation ecosystem. “China is no longer just an important market; it has become a key participant in global innovation,” Zhou from Bayer stated. The country’s capabilities in basic research, clinical trials, and biotech entrepreneurship have reached a point where they can no longer be ignored.
For investors, this signals several key trends.
“In the past, China was more of an important market for global innovation; today, China has become an important participant in global innovation; in the future, China is expected to become one of the important sources of global medical innovation.”
The Unanswered Question
While the strategic shift is clear, its long-term effect on profitability and drug discovery is still unknown. Can this model of deep integration truly accelerate innovation and lower costs, or will it introduce new layers of complexity and regulatory risk? The full answer will only become apparent as these multi-billion dollar deals play out and the localized supply chains prove their resilience. For now, one thing is certain: China is no longer on the sidelines of global pharma; it is now at the center of the stage.
